A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Exclusion Criteria

• •1. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar HCC; other active malignant tumor except HCC within 5 years or simultaneously.
• •2. Evidence of residual lesion, recurrence, and metastasis at randomization.
• •3. Moderate-to-severe ascites with clinical symptoms.
• •4. History of hepatic encephalopathy.
• •5. History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal haemorrhage.
• •6. Active or history of autoimmune disease.
• •7. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity.
• •8. Cardiac clinical symptom or cardiovascular disease that is not well controlled.
• •9. Severe infection within 4 weeks prior to the start of study treatment.
• •10. Subjects with inadequately controlled hypertension or history of hypertensive crisis or hypertensive encephalopathy.
• •11. Thrombosis or thromboembolic event within 6 months prior to the start of study treatment.
• •12. Known genetic or acquired hemorrhage or thrombotic tendency.
• •13. Previous or current presence of metastasis to central nervous system.